From Ex Vivo to In Vivo: Advances in Lentiviral Vector Engineering for CAR-T Therapy - PubMed
3 days ago
- #In vivo gene delivery
- #Lentiviral vectors
- #CAR-T therapy
- CAR-T cell therapy has shown success in treating hematological malignancies but faces challenges in scalability and accessibility due to high costs and complex logistics.
- In vivo CAR-T generation is emerging as a solution to bypass ex vivo manipulation, though it must overcome safety and efficacy hurdles.
- Advances in lentiviral vector design include safety-enhanced, third-generation self-inactivating vector systems and bioengineering strategies for optimized in vivo gene delivery.
- Key strategies for in vivo CAR-T generation include pseudotype engineering, immune-evasion, transgene/payload engineering, and genetic armoring to enhance safety and efficacy.
- Early clinical-stage programs are demonstrating the feasibility of in vivo CAR-T generation, potentially broadening access to advanced cellular immunotherapies.